Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Analyst ratings

<< Previous

Bullboard Posts

Next >>

Comment by pelabooston Sep 20, 2024 3:51pm

137 Views

Post# 36233812

RE:RE:RE:Analyst ratings

Yes CMH. I do not listen any more. Still, given the reports of what was said, I let the few go that I had picked up in the last 10 days. I have always felt this is about GOBLET, and hold a few for news from that trial. There is always the chance that someone may step up, but ONCY seems to be suggesting there is not a lot of interest. I shall just say clarity is not their long suit, and results from GOBLET might just move the lot of them out.

Cheers

PS. mBC may also move someone, but who knows.

<< Previous

Bullboard Posts

Next >>

Canada Nickel unveils second of seven resources planned by mid-2025